| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/03/2000 | CA2338312A1 A subfamily of rna helicases wich are modulators of the fidelity of translation termination and uses thereof |
| 02/03/2000 | CA2338307A1 Pectic substance as a growth factor stabilizer |
| 02/03/2000 | CA2338299A1 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 02/03/2000 | CA2337756A1 Libraries of polyhydroxamates and their analogs |
| 02/03/2000 | CA2337688A1 Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| 02/03/2000 | CA2336238A1 Synthetic peptides and methods of use for autoimmune disease therapies |
| 02/03/2000 | CA2335655A1 Keratinocyte derived interferon |
| 02/03/2000 | CA2335653A1 Molecules associated with cell proliferation |
| 02/03/2000 | CA2335646A1 Genes of the dead box protein family, their expression products and use |
| 02/03/2000 | CA2335345A1 Human calcium regulatory proteins |
| 02/03/2000 | CA2335341A1 Peptide analogues of pacap |
| 02/03/2000 | CA2335340A1 Fsh and fsh variant formulations, products and methods |
| 02/03/2000 | CA2335326A1 Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| 02/03/2000 | CA2335278A1 Method for screening of modulators of calcineurin activity |
| 02/03/2000 | CA2334947A1 Novel peptides for use in immunotherapy of autoimmune diseases |
| 02/03/2000 | CA2334047A1 Hybrid human/rodent igg antibody to cd3, and methods of its construction |
| 02/03/2000 | CA2334042A1 Orphan cytokine receptor |
| 02/02/2000 | EP0976825A1 Transcriptional regulator |
| 02/02/2000 | EP0976823A1 Recombinant expression system and high throughput BioAssay for the therapeutic use of calcineurine-A- alpha, calcineurine-A-beta, calcineurine-A-gamma, calcineurine-B und Cu/Zn-superoxide dismutase respectively for the identification of pharmaceuticals |
| 02/02/2000 | EP0976776A1 Hypertonic aqueous dispersions of unfractioned collagen, a method and a device for the preparation of said dispersions |
| 02/02/2000 | EP0976765A1 Process for the preparation of a protein solution |
| 02/02/2000 | EP0976759A2 Preparation of protein formulations with reduced content of aggregates |
| 02/02/2000 | EP0976394A1 New injectable formulations |
| 02/02/2000 | EP0975963A1 Prostate specific antigen substrates |
| 02/02/2000 | EP0975798A1 Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1 |
| 02/02/2000 | EP0975792A1 Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs |
| 02/02/2000 | EP0975785A1 Adenoviral vectors comprising a modified e4 region but retaining e4orf3 |
| 02/02/2000 | EP0975784A2 Herpes simplex virus u s?3 and icp4 as inhibitors of apoptosis |
| 02/02/2000 | EP0975780A2 Il-2 gene expression and delivery systems and uses |
| 02/02/2000 | EP0975775A2 Regulatory system for inducible expression of genes with lambdoid promoters |
| 02/02/2000 | EP0975772A1 Reagents and methods useful for detecting diseases of the gastrointestinal tract |
| 02/02/2000 | EP0975771A1 Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins |
| 02/02/2000 | EP0975769A1 Novel prostate-associated kallikrein |
| 02/02/2000 | EP0975766A1 Methods and compositions for synthesis of long chain polyunsaturated fatty acids |
| 02/02/2000 | EP0975764A1 A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin |
| 02/02/2000 | EP0975762A1 Type-1 ribosome-inactivating protein |
| 02/02/2000 | EP0975761A1 Recombinant human beta interferon with enhanced solubility |
| 02/02/2000 | EP0975760A1 Motilin homologs |
| 02/02/2000 | EP0975759A1 Human tumor-associated kazal inhibitor |
| 02/02/2000 | EP0975758A1 POLYPEPTIDE HAVING A GTPase REGULATOR ACTIVITY, NUCLEIC ACIDS CODING THEREFOR AND THEIR USE IN DIAGNOSTICS AND THERAPY |
| 02/02/2000 | EP0975756A1 Fibroblasts with a foreign gene-containing composition for treating wounds |
| 02/02/2000 | EP0975754A1 Osteoprotegerin binding proteins and receptors |
| 02/02/2000 | EP0975753A2 $g(b)-AMYLOID PEPTIDE-BINDING PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME |
| 02/02/2000 | EP0975752A1 Human cerberus protein |
| 02/02/2000 | EP0975751A1 A tm4sf human tumor-associated antigen |
| 02/02/2000 | EP0975750A2 Modified retinoblastoma tumor suppressor proteins |
| 02/02/2000 | EP0975749A2 Cc chemokine receptor 5, antibodies thereto, transgenic animals |
| 02/02/2000 | EP0975743A1 Inhibitors for urokinase receptor |
| 02/02/2000 | EP0975680A1 Interactive system for substance presentation and elimination |
| 02/02/2000 | EP0975674A1 Immunotoxins, comprising an onc protein, directed against malignant cells |
| 02/02/2000 | EP0975672A1 Antibodies for inhibiting blood coagulation and methods of use thereof |
| 02/02/2000 | EP0975669A1 Calcitonin receptor-binding peptides |
| 02/02/2000 | EP0975668A1 MODIFIED TNF$g(a) MOLECULES, DNA ENCODING SUCH MODIFIED TNF$g(a) MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNF$g(a) MOLECULES AND DNA |
| 02/02/2000 | EP0975666A2 Compositions and methods for the treatment and diagnosis of breast cancer |
| 02/02/2000 | EP0975665A1 Active substance and composition inhibiting tumorous proliferation in ectoderm derived tissues |
| 02/02/2000 | EP0975663A1 Helicobacter pylori antigens |
| 02/02/2000 | EP0975662A1 Hepatitis c ns3 protease inhibitors |
| 02/02/2000 | EP0975661A1 The proliferation of cell-inhibiting peptide and its use |
| 02/02/2000 | EP0975660A2 COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION BETWEEN alpha-CATENIN and beta-CATENIN |
| 02/02/2000 | EP0975659A1 SELECTIVE FACTOR Xa INHIBITORS |
| 02/02/2000 | EP0975657A1 Method of purifying protein from inclusion bodies |
| 02/02/2000 | EP0975654A1 Composition and method for treatment of cmv infections |
| 02/02/2000 | EP0975650A1 Oligomers which inhibit expression of collagen genes |
| 02/02/2000 | EP0975649A1 Rnase l activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies |
| 02/02/2000 | EP0975600A1 Heterocyclic derivatives and their use as antithrombotic agents |
| 02/02/2000 | EP0975380A2 Membrane system for controlled tissue regeneration in cases of diseases of the peridontium |
| 02/02/2000 | EP0975371A1 Antisense oligonucleotide compositions and methods for the modulation of activating protein 1 |
| 02/02/2000 | EP0975370A2 Composition and method for enhancing transport across biological membranes |
| 02/02/2000 | EP0975369A1 Polyethylene glycol-interferon alpha conjugates for therapy of infection |
| 02/02/2000 | EP0975366A1 Cytoprotective agents comprising monoamine oxidase inhibitors |
| 02/02/2000 | EP0975362A2 Pharmaceutical or food composition for treating pathologies related to graft versus host, allergic or autoimmune reaction |
| 02/02/2000 | EP0975361A1 Methods of modulating immune coagulation |
| 02/02/2000 | EP0975359A1 Potentiation of the immune response through delivery of compounds binding a cytoplasmic dipeptidase |
| 02/02/2000 | EP0975358A2 Method of treating psychological and metabolic disorders using igf or igf/igfbp-3 |
| 02/02/2000 | EP0975357A1 Transdermal delivery system |
| 02/02/2000 | EP0975356A1 Pulsatile delivery of leptin receptor ligands |
| 02/02/2000 | EP0975354A1 Ligand/lytic peptide compositions and methods of use |
| 02/02/2000 | EP0975353A1 Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors |
| 02/02/2000 | EP0975352A1 Protection of living systems from the adverse effects of stress |
| 02/02/2000 | EP0975351A1 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| 02/02/2000 | EP0975335A1 Stable pharmaceutical administration forms of peptides, proteins and nucleic acids |
| 02/02/2000 | EP0975328A1 Method for oral delivery of proteins |
| 02/02/2000 | EP0975226A1 Cell-coated supports |
| 02/02/2000 | EP0975225A1 Fibrocyte-based cellular therapy formulations |
| 02/02/2000 | EP0975216A1 A method for treating papillomavirus infections |
| 02/02/2000 | EP0866859A4 Urogenital sinus derived growth factor nucleotide and amino acid sequences |
| 02/02/2000 | EP0863915B1 Acylated enol derivatives of alpha-ketoesters and alpha-ketoamides |
| 02/02/2000 | EP0796271B1 Dipeptide p-amidinobenzylamides with n-terminal sulfonyl or aminosulfonyl radicals |
| 02/02/2000 | EP0777683B1 Antiprotozoal cyclic tetrapeptides |
| 02/02/2000 | EP0751783B1 Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic use of aminoacetylmercapto derivatives |
| 02/02/2000 | EP0713532B1 Modified maxadilan protein, its preparation and use, and dna encoding the protein |
| 02/02/2000 | EP0713529B1 Growth differentiation factor of the TGF-B family |
| 02/02/2000 | EP0706532B1 Peptides having endothelin antagonictic activity,their preparation and pharmaceutical compositions |
| 02/02/2000 | EP0648126B1 Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma, stomach cancer and breast cancer |
| 02/02/2000 | EP0618812B1 Use of protease nexin-i as an antiinflammatory |
| 02/02/2000 | EP0616535B1 Method of treating viral infections |
| 02/02/2000 | EP0592557B1 Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
| 02/02/2000 | EP0584136B1 Determination of motifs of peptides on mhc molecules |
| 02/02/2000 | EP0558727B1 Bone-growth-stimulating composition |
| 02/02/2000 | EP0397834B1 Method for identifying active domains and amino acid residues in polypeptides and hormone variants |